Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 18
1970 47
1971 65
1972 58
1973 70
1974 67
1975 62
1976 51
1977 45
1978 33
1979 35
1980 42
1981 33
1982 39
1983 55
1984 77
1985 73
1986 74
1987 66
1988 86
1989 98
1990 156
1991 216
1992 295
1993 334
1994 345
1995 306
1996 334
1997 405
1998 387
1999 391
2000 368
2001 344
2002 369
2003 345
2004 397
2005 351
2006 410
2007 384
2008 317
2009 343
2010 375
2011 431
2012 404
2013 345
2014 379
2015 372
2016 302
2017 322
2018 313
2019 317
2020 330
2021 288
2022 265
2023 234
2024 103

Text availability

Article attribute

Article type

Publication date

Search Results

11,857 results

Results by year

Filters applied: . Clear all
Page 1
Glibenclamide as a neuroprotective antidementia drug.
Zubov A, Muruzheva Z, Tikhomirova M, Karpenko M. Zubov A, et al. Arch Physiol Biochem. 2022 Dec;128(6):1693-1696. doi: 10.1080/13813455.2020.1789170. Epub 2020 Jul 11. Arch Physiol Biochem. 2022. PMID: 32654523 Review.
We are aiming here to review available data on the most widely used hypoglycaemic drug, glibenclamide and find possible relationship of its targets to the pathogenesis of cognitive impairment....
We are aiming here to review available data on the most widely used hypoglycaemic drug, glibenclamide and find possible relationship …
[Glibenclamide as a promising agent for prevention and treatment of cerebral edema].
Tsarenko SV, Dzyadz'ko AM, Rybalko SS. Tsarenko SV, et al. Zh Vopr Neirokhir Im N N Burdenko. 2017;81(3):88-93. doi: 10.17116/neiro201781388-93. Zh Vopr Neirokhir Im N N Burdenko. 2017. PMID: 28665392 Free article. Review. Russian.
The article presents a review of the literature on the use of a fundamentally new technique for prevention and treatment of cerebral edema. A drug glibenclamide, which is used to treat type 2 diabetes mellitus, is able to reduce cerebral edema and neuronal damage as eviden …
The article presents a review of the literature on the use of a fundamentally new technique for prevention and treatment of cerebral edema. …
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.
Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Alruwaili M, AlRuwaili R, Albogami SM, Alorabi M, Saad HM, Simal-Gandara J. Batiha GE, et al. Inflammopharmacology. 2023 Feb;31(1):1-7. doi: 10.1007/s10787-022-01087-8. Epub 2022 Nov 23. Inflammopharmacology. 2023. PMID: 36418600 Free PMC article. Review.
Glibenclamide reduces neuroinflammation and associated BBB injury by inhibiting the nod-like receptor pyrin 3 (NLRP3) inflammasome, oxidative stress, and microglial activation. Therefore, glibenclamide through inhibition of NLRP3 inflammasome, microglial activation, …
Glibenclamide reduces neuroinflammation and associated BBB injury by inhibiting the nod-like receptor pyrin 3 (NLRP3) inflammasome, o …
Glibenclamide attenuates brain edema associated with microglia activation after intracerebral hemorrhage.
Shiokawa R, Otani N, Kajimoto R, Igarashi T, Moro N, Suma T, Oshima H, Yoshino A. Shiokawa R, et al. Neurochirurgie. 2022 Dec;68(6):589-594. doi: 10.1016/j.neuchi.2022.07.009. Epub 2022 Aug 10. Neurochirurgie. 2022. PMID: 35963712
OBJECTIVE: Glibenclamide, Sulfonylurea receptor 1 antagonist, reduces brain edema after cerebral hemorrhage. ...Immunohistochemical staining confirmed that glibenclamide attenuated activation of microglia around the hematoma. ...
OBJECTIVE: Glibenclamide, Sulfonylurea receptor 1 antagonist, reduces brain edema after cerebral hemorrhage. ...Immunohistochemical s …
BIIB093 (IV glibenclamide): an investigational compound for the prevention and treatment of severe cerebral edema.
Pergakis M, Badjatia N, Chaturvedi S, Cronin CA, Kimberly WT, Sheth KN, Simard JM. Pergakis M, et al. Expert Opin Investig Drugs. 2019 Dec;28(12):1031-1040. doi: 10.1080/13543784.2019.1681967. Epub 2019 Oct 24. Expert Opin Investig Drugs. 2019. PMID: 31623469 Free PMC article. Review.
Preclinical studies have shown that SUR1-TRPM4 channels play a critical role in edema formation and brain swelling in LHI and TBI. Glibenclamide, a sulfonylurea drug and potent inhibitor of SUR1-TRPM4, was reformulated for intravenous injection, known as BIIB093.Areas cove …
Preclinical studies have shown that SUR1-TRPM4 channels play a critical role in edema formation and brain swelling in LHI and TBI. Gliben …
Glibenclamide Alleviates LPS-Induced Acute Lung Injury through NLRP3 Inflammasome Signaling Pathway.
Yang J, Yang J, Huang X, Xiu H, Bai S, Li J, Cai Z, Chen Z, Zhang S, Zhang G. Yang J, et al. Mediators Inflamm. 2022 Feb 11;2022:8457010. doi: 10.1155/2022/8457010. eCollection 2022. Mediators Inflamm. 2022. PMID: 35185385 Free PMC article.
Herein, we aimed to explore the effect of glibenclamide in vivo and in vitro on the development of LPS-induced ALI in a mouse model. ...Of note, glibenclamide had no effect on the secretion of TNF-alpha in vivo nor in vitro, implicating that its anti-inflammatory ef …
Herein, we aimed to explore the effect of glibenclamide in vivo and in vitro on the development of LPS-induced ALI in a mouse model. …
Mechanism of Action of Novel Glibenclamide Derivatives on Potassium and Calcium Channels for Insulin Secretion.
Frederico MJS, Castro AJG, Menegaz D, Murat CB, Mendes CP, Mascarello A, Nunes RJ, Silva FRMB. Frederico MJS, et al. Curr Drug Targets. 2017;18(6):641-650. doi: 10.2174/1389450117666160615084752. Curr Drug Targets. 2017. PMID: 27316908 Review.
Glibenclamide is widely used and remains a cornerstone and an effective antihyperglycemic drug. ...Furthermore, the role of glibenclamide-based novel structures that promise less excitability of beta-cell in a long-term treatment with effectiveness and safety for di …
Glibenclamide is widely used and remains a cornerstone and an effective antihyperglycemic drug. ...Furthermore, the role of gliben …
Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk.
Gao R, Yang T, Xu W. Gao R, et al. Expert Opin Investig Drugs. 2017 Jul;26(7):853-864. doi: 10.1080/13543784.2017.1333104. Epub 2017 Jun 1. Expert Opin Investig Drugs. 2017. PMID: 28541801 Review.
Metformin, a first-line medication for type 2 diabetes mellitus, arouses growing concerns on its anti-cancer effect. However, data regarding the effect of glibenclamide on tumor growth and cancer risk are less consistent, which may be a potential anti-cancer drug. Areas co …
Metformin, a first-line medication for type 2 diabetes mellitus, arouses growing concerns on its anti-cancer effect. However, data regarding …
Glibenclamide promoted functional recovery following sciatic nerve injury in male Wistar rats.
Ferdowsi S, Abdolmaleki A, Asadi A, Zahri S. Ferdowsi S, et al. Fundam Clin Pharmacol. 2022 Dec;36(6):966-975. doi: 10.1111/fcp.12796. Epub 2022 May 20. Fundam Clin Pharmacol. 2022. PMID: 35524424
Following glibenclamid injection, the mRNA levels of neurotrophic factors (NGF and BDNF) are raised. ...These results showed that glibenclamide therapy by decreasing the proinflammatory and oxidant factors may enhance the nerve regeneration. ...
Following glibenclamid injection, the mRNA levels of neurotrophic factors (NGF and BDNF) are raised. ...These results showed that …
Management of sulfonylurea-treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer.
Shepherd M, Brook AJ, Chakera AJ, Hattersley AT. Shepherd M, et al. Diabet Med. 2017 Oct;34(10):1332-1339. doi: 10.1111/dme.13388. Epub 2017 Jun 13. Diabet Med. 2017. PMID: 28556992 Free PMC article. Review.
The optimum treatment for HNF1A/HNF4A maturity-onset diabetes of the young and ATP-sensitive potassium (K(ATP) ) channel neonatal diabetes, outside pregnancy, is sulfonylureas, but there is little evidence regarding the most appropriate treatment during pregnancy. Glibenclamid …
The optimum treatment for HNF1A/HNF4A maturity-onset diabetes of the young and ATP-sensitive potassium (K(ATP) ) channel neonatal diabetes, …
11,857 results
You have reached the last available page of results. Please see the User Guide for more information.

Searches related to "glibenclamide"